Wall Street Journal -- Pacira Pharmaceuticals Inc. generated little interest among investors on its first day of trading Thursday, even after it cut its offering price in half.The company’s stock opened at $7 a share on the Nasdaq, flat with its initial public offering price. It sold six million shares, nearly two million more than expected, but at a greatly reduced price. The company had originally set out to sell its stock within a $14 to $16 range.
